Gilead Sciences, Inc. $GILD Shares Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,972,668 shares of the biopharmaceutical company’s stock after buying an additional 10,020 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Gilead Sciences were worth $443,076,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Client 1ST Advisory Group LLC boosted its stake in shares of Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 69 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after purchasing an additional 74 shares during the last quarter. Financial Connections Group Inc. increased its stake in shares of Gilead Sciences by 30.2% in the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 76 shares during the period. Wilkerson Advisory Group LLC increased its stake in shares of Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 78 shares during the period. Finally, HBW Advisory Services LLC raised its holdings in Gilead Sciences by 2.4% in the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 79 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock valued at $15,877,860 over the last three months. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on GILD. Cantor Fitzgerald raised their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday. Wells Fargo & Company increased their price objective on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a report on Friday. Truist Financial raised their target price on Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $169.19.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Price Performance

GILD stock opened at $170.68 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company’s 50-day moving average is $150.87 and its 200-day moving average is $139.79. The stock has a market capitalization of $211.63 billion, a PE ratio of -54.01 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $175.65.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.47 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.